Jump to: | Authorized Access | | | Attribution | | | Authorized Requests |
- Study Description
-
Important Links and Information
-
Request access via Authorized Access
- Instructions for requestors
- Data Use Certification (DUC) Agreement
- Talking Glossary of Genetic Terms
Despite the potential of whole-genome sequencing (WGS) to improve patient diagnosis and care, the empirical value of WGS in the cancer genetics clinic is unknown. We performed WGS on members of two cohorts of cancer genetics patients: those with BRCA1/2 mutations (n = 176) and those without (n = 82). Initial analysis of potentially pathogenic variants (PPVs, defined as nonsynonymous variants with allele frequency < 1% in ESP6500) in 163 clinically-relevant genes suggested that WGS will provide useful clinical results. This is despite the fact that a majority of PPVs were novel missense variants likely to be classified as variants of unknown significance (VUS). Furthermore, previously reported pathogenic missense variants did not always associate with their predicted diseases in our patients. This suggests that the clinical use of WGS will require large-scale efforts to consolidate WGS and patient data to improve accuracy of interpretation of rare variants. While loss-of-function (LoF) variants represented only a small fraction of PPVs, WGS identified additional cancer risk LoF PPVs in patients with known BRCA1/2 mutations and led to cancer risk diagnoses in 21% of non-BRCA cancer genetics patients after expanding our analysis to 3209 ClinVar genes. These data illustrate how WGS can be used to improve our ability to discover patients' cancer genetic risks. "Reprinted from doi:10.1016/j.ebiom.2014.12.003, with permission from EBioMedicine."
- Study Design:
- Prospective Longitudinal Cohort
- Study Type:
- Cohort
- dbGaP estimated ancestry using GRAF-pop
- Total number of consented subjects: 258
- Subject Sample Telemetry Report (SSTR)
-
Request access via Authorized Access
- Authorized Access
- Publicly Available Data
- Link to other NCBI resources related to this study
- Study Inclusion/Exclusion Criteria
Individuals from the cancer genetics clinics of the University of Texas Southwestern Medical Center (UTSW) and the Ohio State University (OSU) cancer genetics programs were recruited to the study following informed consent approved by the Institutional Review Boards of both institutions. Only unrelated individuals were included in this study. Blood samples were obtained and de-identified. Subsequent genetic results were not returned to participants.
- Molecular Data
-
Type Source Platform Number of Oligos/SNPs SNP Batch Id Comment Whole Genome Sequencing Complete Genomics Assembler Version 2.4.0.43 N/A N/A - Study History
First samples collected March 2003. Additional patients recruited at Ohio State University, Columbus, OH, and University of Texas Southwestern Medical Center, Dallas, TX, continued through 2013. First samples submitted to Complete Genomics, Inc. in December 2012. Study ended October 2014.
- Selected Publications
- Diseases/Traits Related to Study (MeSH terms)
-
- Primary Phenotype: Neoplasms
- Breast Neoplasms
- Ovarian Neoplasms
- Peritoneal Neoplasms
- Skin Neoplasms
- Esophageal Neoplasms
- Thyroid Neoplasms
- Urinary Bladder Neoplasms
- Endometrial Neoplasms
- Fallopian Tube Neoplasms
- Melanoma
- Testicular Neoplasms
- Bile Duct Neoplasms
- Lung Neoplasms
- Colonic Neoplasms
- Adrenocortical Carcinoma
- Carcinoma, Renal Cell
- Colonic Polyps
- Adenomatous Polyposis Coli
- Lymphoma, Large B-Cell, Diffuse
- Pheochromocytoma
- Paraganglioma
- Leiomyoma
- Hemangioblastoma
- Hyperparathyroidism
- Pancreatic Neoplasms
- Vulvar Neoplasms
- Brain Neoplasms
- Liver Neoplasms
- Kidney Neoplasms
- Prostatic Neoplasms
- Glioblastoma
- Oncocytoma, renal
- Links to Related Genes
- Authorized Data Access Requests
- Study Attribution
-
-
Principal Investigator
- Theodora S. Ross, MD, PhD. Department of Internal Medicine, UT Southwestern Medical Center, Dallas, TX, USA, and Department of Cancer Genetics, UT Southwestern Medical Center, Dallas, TX, USA.
-
Institute
- Samantha B. Foley. Department of Internal Medicine, UT Southwestern Medical Center, Dallas, TX, USA.
- Jonathan J. Rios. Sarah M. and Charles E. Seay Center for Musculoskeletal Research, Texas Scottish Rite Hospital for Children, Dallas, TX, USA. Department of Pediatrics, McDermott Center for Human Growth and Development, and Department of Orthopaedic Surgery, UT Southwestern Medical Center, Dallas, TX, USA.
- Victoria E. Mgbemena. Department of Internal Medicine, UT Southwestern Medical Center, Dallas, TX, USA.
- Linda S. Robinson. Department of Cancer Genetics, UT Southwestern Medical Center, Dallas, TX, USA.
- Heather L. Hampel. Department of Human Genetics, Ohio State University, Columbus, OH, USA.
- Amanda E. Toland. Department of Human Genetics, Ohio State University, Columbus, OH, USA.
- Leslie Durham. Department of Internal Medicine, UT Southwestern Medical Center, Dallas, TX, USA.
-
Funding Source
- Clinical Scientist Award ID# 1007448. Burroughs Wellcome Fund, Research Triangle Park, NC, USA.
- Peter Bradley Carlson Charitable Trust, San Antonio, TX, USA.
- Jeanne Ann Plitt Professorship in Breast Cancer Research, Dallas, TX, USA. UT Southwestern Medical Center, Dallas, TX, USA.
- H. Ben and Isabelle T. Decherd Chair in Internal Medicine, Dallas, TX, USA. UT Southwestern Medical Center, Dallas, TX, USA.
- UL1TR001105. National Institutes of Health, Bethesda, MD, USA.
-
Principal Investigator